Simcere Pharmaceutical Group Ltd
S2P
Company Profile
Business description
Simcere Pharmaceutical Group Ltd is engaged in the R&D, production, and commercialization of pharmaceuticals focused on generic pharmaceuticals. It has a diversified product portfolio focused on therapeutic areas, including, oncology (including cell therapy), nervous system diseases, autoimmune diseases, and antiinfection. The company's products include Endostar, Enweida, Iremod, Sanbexin and Others.
Contact
No. 699-18, Xuanwu Road
Xuanwu District
Jiangsu Province
Nanjing210042
CHNT: +86 2585566666
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
6,815
Stocks News & Analysis
stocks
Moated ASX player’s future growth prospects look solid
We expect the strong earnings momentum at this company to continue, with shares looking fairly valued.
stocks
Ask the analyst: Can this genius product create the next ASX software king?
SiteMinder’s newly released product for hotel owners and travel agents could widen its moat and see revenue accelerate further.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,062.70 | 59.80 | -0.66% |
| CAC 40 | 7,786.98 | 31.24 | -0.40% |
| DAX 40 | 23,359.18 | 29.94 | 0.13% |
| Dow JONES (US) | 46,018.32 | 260.42 | 0.57% |
| FTSE 100 | 9,208.37 | 12.71 | 0.14% |
| HKSE | 26,851.03 | 412.52 | 1.56% |
| NASDAQ | 22,261.33 | 72.63 | -0.33% |
| Nikkei 225 | 45,277.43 | 375.16 | 0.84% |
| NZX 50 Index | 13,132.39 | 102.50 | -0.77% |
| S&P 500 | 6,600.35 | 6.41 | -0.10% |
| S&P/ASX 200 | 8,780.30 | 68.20 | -0.77% |
| SSE Composite Index | 3,885.81 | 9.47 | 0.24% |